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Outcome study of renal biopsy patients in Okinawa, Japan.
Here we report a community-based epidemiologic study of pa-
tients who received renal biopsy in Okinawa, Japan between
1967 and 1994. The total number of cases was 2832 (1395 men
and 1437 women), and the mean (SD) age at biopsy was 30.0
(10.0) years (range 1.0 to 88.0 years). The most common clin-
ical indications for renal biopsy were proteinuria/hematuria
(46.7%), nephrotic syndrome (21.2%), acute glomerulonephri-
tis (10.1%), and systemic lupus erythematosus (7.5%). Patients
who received renal biopsy between 1985 and 1994 (N = 1480)
were much less likely to have acute glomerulonephritis than pa-
tients treated between 1967 and 1984 (N = 1352); the rates of
proteinuria/hematuria, renal failure, and diabetes mellitus were
slightly higher in the later period. Okinawa patients who began
dialysis between 1971 and 2000 (N = 5246) were also studied.
Among them, a total of 468 patients (260 men and 208 women)
began dialysis after renal biopsy. The cumulative incidence of
end-stage renal disease (ESRD) among these patients was 17%
in 17 years. Half of these patients developed ESRD in the
5.8 years after renal biopsy. Among the dialysis patients, the
biopsy rate was 12.6% in chronic glomerulonephritis, 1.7% in di-
abetes mellitus, 2.6% in nephrosclerosis, and 52.1% in systemic
lupus erythematosus. The diagnoses of primary renal diseases
were primarily made clinically. The survival rate after starting
dialysis therapy was slightly better in those with than in those
without renal biopsy but this finding was not statistically signif-
icant (adjusted hazards ratio 0.855, 95% CI 0.711–1.028, P =
0.095). The clinical significance of renal biopsy, other than its
provision of histologic evidence, remains to be shown.
Renal biopsy is a common diagnostic procedure in
nephrology, and can provide essential histologic evidence
of renal disease. Renal biopsy can allow the selection
of appropriate treatment, and therefore the prevention
of future disease progression. However, late referral to
nephrologist is common [1, 2]. In such cases, renal biopsy
is often not indicated due to significant renal dysfunc-
tion, small kidneys, and poor prognosis. In patients with
asymptomatic proteinuria/hematuria, the progression of
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renal failure is usually slow; therefore, the clinical benefit
of renal biopsy is difficult to prove. Paone and Meyer [3]
showed that only in 19% of such cases did renal biopsy
immediately lead to major therapeutic decisions. Renal
biopsy is costly and potentially hazardous, so its potential
benefits should be assessed [4]. Few epidemiologic stud-
ies have examined the long-term outcomes after renal
biopsy, especially of the risk of progression to end-stage
renal disease (ESRD) [5].
The number of ESRD patients has recently steadily
been increasing. The aim of this study was to gather infor-
mation about the demographic and clinical characteristics
of patients who received renal biopsy in Okinawa, Japan
within the past 28 years. The epidemiologic outcomes in
primary glomerulonephritis may depend on age and year
[6]. We examined the role of renal biopsy in preventing
ESRD, and also the impact of renal biopsy on survival
among patients who had already started dialysis therapy.
METHODS
Study design
The computer registry of renal biopsy was established
with the collaboration of the physicians listed in the
Acknowledgments section. The registry includes every
renal biopsy patient ever performed in Okinawa, Japan,
from the first case in 1967 to 1994. The indications for re-
nal biopsy and the clinical demographics of the patients
were examined. These factors were compared for pa-
tients receiving renal biopsy between 1967 and 1984 ver-
sus between 1985 and 1994. A separate community-based
ESRD registry includes every ESRD patient treated in
Okinawa since 1971. The two registries were used to iden-
tify renal biopsy patients who later developed ESRD.
This identification was confirmed through the review of
medical records. The cumulative incidence of ESRD after
renal biopsy was calculated. Survival curves for patients
with and without renal biopsy who had started dialysis
therapy were compared.
Okinawa is located in the southernmost part of Japan
and consists of subtropical islands. The census population
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has increased from 1.04 million in 1975, to 1.11 million
in 1980, 1.18 million in 1985, 1.22 million in 1990, and
1.26 million in 1995. Okinawa contains about 1% of the
total population of Japan. In the 1985 census, the popu-
lation was 1,179,097 (581,102 men and 597,995 women).
The age distribution of the population was under 10 years
of age, 207,401 (106,207 male and 101,194 female); 10 to
19 years, 211,484 (107,675 male and 103,809 female); 20
to 39 years, 363,579 (186,371 male and 177,208 female);
40 to 59 years, 254,746 (126,610 male and 128,136 female);
60 to 79 years, 117,582 (47,082 male and 70,500 female);
and 80 years and over, 23,797 (6,948 male and 16,849 fe-
male). The life expectancy of neonates was 76.3 years for
males and 83.7 years for females in 1985. This was higher
than the average life expectancy of Japanese neonates,
which was 74.9 years for males and 80.7 years for fe-
males. Due to its location and culture, most residents of
Okinawa have lived only in Okinawa. This is especially
true for patients with serious diseases such as stroke,
acute myocardial infarction, and ESRD.
Renal biopsy registry
All renal biopsy cases in Okinawa were investigated
with the full collaboration of all local medical facili-
ties. Dr. F. Miyasato performed the first renal biopsy in
Okinawa in 1967. Since then, more than 3200 biopsies
have been performed and included in the registry. If a
patient received more than one biopsy, only the first was
included in the registry. We included a few biopsy cases in
which patients received renal biopsy while living outside
Okinawa and then returned to Okinawa. In 1994 there
were 19 renal biopsy facilities in Okinawa. Open renal
biopsy cases were included if this procedure was indi-
cated for medical reasons. Biopsies of renal grafts and in
cases of trauma or tumors were excluded. The registry
computer files included information on patients’ name,
gender, birth date, date of biopsy, indication for biopsy,
and histologic diagnosis.
The indications for renal biopsy and the available
equipment for immunofluorescent and/or electron mi-
croscopy varied among medical facilities. In the past
28 years there have been many pathologists and nephrol-
ogists in Okinawa. Therefore, in this study, we sought
to collect as many relevant medical documents from
the time of renal biopsy as possible. The indications for
renal biopsy were categorized into nine subgroups:
asymptomatic proteinuria/hematuria, acute glomeru-
lonephritis, nephrotic syndrome, diabetes mellitus (DM),
systemic lupus erythematosus (SLE), rheumatoid arthri-
tis, renal dysfunction, hypertension, and other reasons.
This last category included those who had other sys-
temic diseases causing renal damage or who had no spec-
ified indications for renal biopsy. Most cases of asymp-
tomatic proteinuria/hematuria were referred from health
examinations in the workplace or school. Such screen-
ing has been conducted since 1972; we collaborated with
the major local medical screening institute. The diag-
nosis of acute glomerulonephritis was made clinically
based on the rapid onset of edema, hypertension, and
proteinuria/hematuria occurring after an upper respi-
ratory or skin infection. The nephrotic syndrome pre-
sented with heavy proteinuria (more than 3.5 g/day, or 4+
proteinuria).
To evaluate the evolution of the incidence of primary
renal disease according to time period and patient age, we
divided patients into groups based on the year in which
they received renal biopsy (1967 to 1984 and 1985 to
1994). The mean (SD) age at the time of renal biopsy
increased slightly from 29.9 (10.0) years in 1967 to 1984,
to 34.4 (11.1) years in 1985 to 1994. The ratio of men to
women did not change significantly, from 1.0 in 1967 to
1984, to 1.1 in 1985 to 1994.
Okinawa Dialysis Study (OKIDS) registry
Every case of ESRD since 1971 was filed in the OKIDS
registry. Patients with ESRD who survived at least
1 month on scheduled dialysis therapy are included in
the registry [7, 8]. Patients dying within 1 month of the
start of dialysis are not included in the registry because it
is unknown whether their renal function was improving
and whether other medical conditions accounted for their
rapid demise. Virtually all pertinent clinical information
for new dialysis patients and information on the medi-
cal events among previously-registered dialysis patients
were collected by the collaborating physicians acknowl-
edged below. The registry was updated at least twice a
year to include information on medical events such as
death, renal transplantation, and patient transfer out of
Okinawa. Where necessary, other information was ob-
tained through nurses, medical clerks, and the patients
themselves. All patients were followed up until a ma-
jor medical event or January 2001, whichever occurred
first, and we verified all outcomes. Because Okinawa is
made up of subtropical islands that are separated from
mainland Japan, there was little migration of patients. By
the end of 2000, there were 46 dialysis units in Okinawa:
nine in the public sector, 17 in private hospitals, and 20 in
clinics.
Criteria for the diagnosis of primary causes of ESRD
were neither simple nor standardized. Therefore, the
medical records relevant to renal biopsy were further re-
viewed, and patients were grouped into one of six disease
categories. Chronic glomerulonephritis was diagnosed
when proteinuria and/or hematuria was noted before the
onset of hypertension and renal failure. Nephrosclero-
sis was diagnosed when hypertension or major vascular
disease was documented before the onset of renal fail-
ure. DM nephropathy was diagnosed clinically by a long
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Fig. 1. Annual number of renal biopsies in Okinawa, Japan, from 1967
to 1994.
history of DM, presence of DM retinopathy, and the use
of insulin [9]. SLE was diagnosed according to the criteria
of the American Rheumatism Association [10]. Polycys-
tic kidney disease was diagnosed, after chart review, by
the presence of multiple cysts and a family history of the
disease. A sixth category, “other” disease, was used for
patients who did not fall into one of the aforementioned
disease categories.
Statistical analysis
Data are expressed as mean ± SD. P values of 0.05
or less were considered statistically significant. Data on
the Okinawa population were available through annual
government reports and the census. Unpaired t test and
chi-squared tests were used to compare discrete variables
between the groups. Kaplan-Meier survival curves were
obtained for dialysis patients with and without a history of
renal biopsy. Cox proportional hazard analysis was used
to compare survival rates after adjusting for possible con-
founding variables such as age, gender, and renal disease.
RESULTS
The annual number of cases of renal biopsy increased
linearly, as shown in Figure 1. Until 1980, renal biopsy was
only performed in one hospital. The indications for renal
biopsy are summarized in Table 1. Proteinuria/hematuria
was the most common indication (46.7% of renal biopsy
patients), followed by nephrotic syndrome in 21.2% of
patients. Other indications included chronic interstitial
nephritis (N = 44), renal tubular acidosis (N = 22), pol-
yarteritis nodosa (N = 12), multiple myeloma (N = 4),
liver cirrhosis (N = 2), and “not specified” (N = 32).
The mean age at renal biopsy increased significantly
over time, from 29.9 years in 1967 to 1984, to 34.6 years
in 1985 to 1994 (P < 0.0001). There was no significant
Table 1. Clinical indications for renal biopsy in Okinawa, Japan
Clinical diagnosis Number of renal biopsies
Proteinuria/hematuria 1321 (46.7%)
Nephrotic syndrome 601 (21.2%)
Acute glomerulonephritis 286 (10.1%)
Systemic lupus erythematosus 213 (7.5%)
Renal failure 129 (4.5%)
Diabetes mellitus 54 (1.9%)
Rheumatoid arthritis 47 (1.7%)
Hypertension 35 (1.2%)
Other reasons 146 (5.2%)
Total 2832 (100%)
Study period was from 1967 to 1994. Only the first renal biopsy in each case
was counted.
Table 2. Changes in clinical background of patients who received
renal biopsy in Okinawa, Japan
Year 1967 to 1984 1985 to 1994 P value
Number 1352 1480
Men (%) 645 (47.7%) 750 (50.6%) NS
Age years
Mean (SD) 29.9 (15.7) 34.6 (19.4) <0.0001
Range 2∼84 1∼88
Clinical diagnosis <0.0001
Proteinuria/hematuria 555 (41.0%) 766 (51.8%)
Nephrotic syndrome 308 (22.8%) 293 (19.8%)
Acute glomerulonephritis 247 (18.3%) 39 (2.6%)
Systemic lupus 99 (7.3%) 114 (7.6%)
erythematosus
Renal failure 49 (3.6%) 80 (5.4%)
Diabetes mellitus 17 (1.3%) 37 (2.5%)
Rheumatoid arthritis 21 (1.6%) 26 (1.8%)
Hypertension 10 (0.7%) 25 (1.7%)
Others 46 (3.4%) 100 (6.8%)
NS is not significant.
change in the ratio of men to women renal biopsy pa-
tients. The proportion of renal biopsy cases indicated by
proteinuria/hematuria, renal failure, and DM increased
significantly during this period, but those indicated by
acute glomerulonephritis decreased from 18.3% to 2.6%
(Table 2).
Among the 5246 patients who developed ESRD be-
tween 1971 and 2000, 468 were identified in the renal
biopsy registry (Table 3). The distribution of renal dis-
eases in these patients, diagnosed clinically, was different
for those with versus those without renal biopsy.
The mean (SD) time from renal biopsy to the start of
dialysis was 85.9 (66.9) months (range 1 to 389 months).
The time to dialysis was longest for patients with acute
glomerulonephritis, and shortest for those with DM
(Fig. 2). The cumulative incidence of ESRD was 17%
in 17 years after renal biopsy (Fig. 3). Half of the patients
began dialysis within 5.8 years of renal biopsy.
Among dialysis patients, the actual survival rate was
better in those with than in those without a history of
renal biopsy (Fig. 4). However, this difference was not
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Table 3. Comparison of the characteristics of end-stage renal disease
(ESRD) patients in Okinawa, Japan, according to their history of
renal biopsy
ESRD patients
Renal Renal
biopsy (+) biopsy (−)
N = 468 N = 4778 P value
Men % 55.6 56.9 NS
Age at start of dialysis years
Mean (SD) 41.8 (15.9) 55.9 (16.7) <0.0001
Renal disease % <0.0001
Chronic glomerulonephritis 67.7 44.9
Diabetes mellitus 9.4 32.6
Nephrosclerosis 2.6 11.0
Systemic lupus erythematosus 13.0 1.0
Polycystic kidney disease 0.7 2.5
Others 6.6 8.0
NS is not significant. ESRD patients were included in the registry between
1972 and 2000. The diagnosis of renal disease was primarily made clinically.
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Fig. 2. Time from renal biopsy to the start of dialysis according to the
indication for renal biopsy. Renal biopsy was completed between 1967
and 1994, and patients were followed to 2000. Data are expressed as
mean (SEM). Abbreviations are: AGN, acute glomerulonephritis; NS,
nephrotic syndrome; DM, diabetes mellitus; SLE, systemic lupus ery-
thematosus; UP/UH, asymptomatic proteinuria/hematuria.
statistically significant (adjusted relative risk 0.855, 95%
CI 0.711–1.028, P = 00949).
Renal biopsy is seldom performed in dialysis patients.
We compared our results to those of the Japanese Society
for Dialysis Therapy (JSDT) registry. The JSDT registry
contains information on renal biopsy cases throughout
Japan between 1990 and 2000. The renal biopsy rate was
higher in Okinawa than in all of Japan (Table 4). This rate
was higher in Okinawa than in all of Japan for patients
with chronic glomerulonephritis and SLE, and lower for
patients with DM and nephrosclerosis.
DISCUSSION
The main finding of this study is that the clinical in-
dications for renal biopsy in our district have changed.
Whether this is directly related to changes in the inci-
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Fig. 3. Cumulative incidence of end-stage renal disease (ESRD) in pa-
tients who had renal biopsies in Okinawa, Japan, between 1967 and
1994. The follow-up period extended to 2000.
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Fig. 4. Survival curves for dialysis patients who did or did not have
renal biopsy (RBX) in Okinawa, Japan. Study period was from 1971 to
2000.
dences of renal diseases is not clear. The decreased in-
cidence of renal biopsy due to acute glomerulonephritis
may reflect the known decrease in the incidence of acute
glomerulonephritis that has resulted from improvements
in social conditions and the wider use of antibiotics. The
control of Okinawa returned from the United States to
Japan in 1972, and mass health screenings were started
then. National screening programs for school-age chil-
dren and insurance applicants cover almost the entire
population; these programs make renal biopsy financially
acceptable [11]. The number of units in Okinawa per-
forming renal biopsy increased from 1 to 19 during the
study period. The renal biopsy rate has been over 100 per
million people since 1985.
We found that the cumulative incidence of ESRD
was about 17% in 17 years after renal biopsy. Very few
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Table 4. Comparison of renal biopsy statistics for dialysis patients in
the Japanese Society for Dialysis Therapy (JSDT) versus in the
Okinawa Dialysis Study (OKIDS) registry
JSDT OKIDS
Population in millionsa 126.9 1.32
Number of dialysis patients 285,854 3482
Number of renal biopsies 15,160 280
Total renal biopsy rate 5.3% 8.0%
Renal biopsy rate by renal diseaseb
Chronic glomerulonephritis 8.2% 12.6%
Diabetes mellitus 3.4% 1.7%
Nephrosclerosis 3.3% 2.6%
Systemic lupus erythematosus 12.8% 52.1%
Study period was from 1990 to 2000. JSDT data were obtained with permission.
The renal biopsy rate was calculated as the number of renal biopsy patients
divided by the total number of dialysis patients. aPopulation in 2000; bRenal
disease was primarily diagnosed clinically.
patients developed ESRD 20 years or more after renal
biopsy. We did not gather information on the patients who
died before they were entered into the ESRD registry;
therefore, we underestimated the impact of renal biopsy
on developing ESRD. The Okinawa ESRD program was
started in 1971 and founded fully in 1972. Before this,
patients with ESRD occasionally had been treated with
intermittent peritoneal dialysis. These patients were not
counted in this study. The mean time from renal biopsy
to the start of dialysis was 85.9 months (range 1 to 389
months) in patients who developed ESRD. Half of these
patients had entered the dialysis program within 5.8 years
of renal biopsy. This timing was similar to that previously
reported for screened subjects with a serum creatinine
≥2.0 mg/dL [12]. We have previously examined the pre-
dictors of ESRD among participants in mass screening,
and found that proteinuria was the most potent predictor
of ESRD [13, 14].
The renal biopsy rate in ESRD patients with SLE was
much higher in Okinawa than in all of Japan. The in-
cidence of SLE is high in the southern part of Japan. In
Okinawa, the estimated annual incidence of SLE per mil-
lion populations was 16.0 in 1972 and 46.7 in 1991 in fe-
males, and 4.2 in 1972 and 8.3 in 1991 in males. A decrease
in the mortality rate of SLE patients may result in an in-
crease in the prevalence of SLE-induced renal disease
and, ultimately, ESRD. We found that the cumulative in-
cidence of ESRD was 21.0% in the first 20 years after the
diagnosis of SLE [10].
The survival rates of dialysis patients were not statis-
tically different for those with or without renal biopsy.
Patients who underwent renal biopsy usually had been
treated in the unit in which the renal biopsy was done.
Therefore, these renal biopsy patients are not late refer-
rals. It has been reported that late referral is common,
and that patients who were referred late had worse sur-
vival rates after beginning dialysis than early referral pa-
tients [1, 2]. The present study confirmed our previous
finding that comorbid illness, but not late referral, was
a significant predictor of survival in chronic dialysis pa-
tients [15]. This discrepancy from previous reports out-
side Japan may be due to differences in medical services
and/or different incidences of comorbid conditions such
as heart disease and atherosclerosis.
There are several limitations of the current study. First,
full information about histologic diagnosis, immunoflu-
orescence, and electron microscopy were not available
in all patients. Most biopsy reports in the 1960s and
1970s did not document the number of glomeruli ex-
amined. Our renal biopsy registry includes information
from many centers over a long study period; histologic
diagnostic criteria varied with pathologist and nephrolo-
gist and with time. Among the renal biopsy patients with
proteinuria/hematuria or nephrotic syndrome, the histo-
logic diagnosis was membranous glomerulosclerosis in
169 patients and focal glomerulosclerosis in 30 patients.
The cumulative incidence of ESRD was 18.3% for mem-
branous glomerulosclerosis, 43.3% for focal glomeru-
losclerosis, and 14.5% for proteinuria/hematuria. Xie
et al [16] reported that 19.5% of patients with IgA
nephropathy (N = 118) began dialysis in the 15 years of
follow-up.
The second limitation of this study is that the clinical
and laboratory information available at the time of re-
nal biopsy were not complete. Therefore, whether our
observed differences in the time to the development of
ESRD after renal biopsy were due to renal disease it-
self, renal function, or differences in treatment is not
clear [17]. We previously examined the effect of hyper-
tension on the risk of developing ESRD [18]. We found
that among patients with severe hypertension at the time
of screening the cumulative incidence of ESRD was 1.7%
in 17 years’ follow-up.
The third main limitation is that we did not examine
the treatment administered after renal biopsy. The true
impact of biopsy diagnosis on renal survival therefore is
not clear. The treatment of hypertension has previously
been shown to preserve renal function. Angiotensin-
converting enzyme (ACE) inhibitors, which offer renal
protection, have been widely used in Japan since 1983,
and angiotensin receptor blockade since 1998. The an-
nual incidence of ESRD due to chronic glomerulonephri-
tis has been stable during the past 20 years, but the mean
age at start dialysis has gradually increased in Japan [19].
These trends may be explained, at least in part, by treat-
ment with these drugs.
Finally, in the last 20 years, socioeconomic conditions
and lifestyle have changed dramatically in Okinawa. The
use of antibiotics and improved social conditions have
contributed to the decrease in the incidence of infection-
related renal diseases such as acute glomerulonephritis.
Sporadic cases of malaria and leprosy were reported in
1994 in Okinawa. The control of environmental factors
that increase the risk of primary glomerular disease [6]
has improved tremendously in our region.
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CONCLUSION
We have documented the clinical demographics and re-
nal outcomes of patients in our community-based renal
biopsy registry. The number of renal biopsies performed
is increasing linearly; renal biopsy is an established di-
agnostic tool in clinical nephrology. However, it remains
to be shown how renal biopsy findings affect treatment
decisions and the progression of renal disease. More in-
formation is needed to clarify the effect of renal biopsy
on renal survival. However, we believe that renal biopsy
is useful for improving patient compliance in nephrologic
treatment regimens, including lifestyle modification and
drug treatment.
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